OptiBiotix Health PLC Launch of Slimbiome in Nutri-bites

TIDMOPTI

OptiBiotix Health PLC

08 March 2018

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Launch of Slimbiome(R) in Nutri-bites(R)

OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, and high cholesterol, announces the launch of its award winning SlimBiome(R) in Nutri-Bites(R) with its US partner, Cereal Ingredients ("CII"), at the 2018 Natural Products Expo West & Engredea. The exhibition is the world's largest trade show for organic, natural and healthy products and typically attract more than 80,000 food and ingredient buyers from around the world. OptiBiotix will join CII at stand 3788.

OptiBiotix has partnered with specialty ingredients manufacturer CII Ingredients, to launch its patented weight management technology, SlimBiome(R) in CII's Nutri-Bites(R) range of cereal based food products. This extends SlimBiome(R) applications from snack bars and shakes to breakfast cereals and bakery products (e.g. cookies, cakes and tortillas) as well as increasing the range of options for healthy snacks, yoghurts and cereal bars.

Products in the Nutri-Bites(R) range contain expanded cereal pieces and are formulated with a choice of protein sizes and content. These can be applied to granola and snack mix inclusions, nutritional and cereal bars and coated snacks, or just used as a healthy crunch topping.

This is a continuation of OptiBiotix's focus on the US market following last years supply & manufacturing Aareement with CII, announced on 12 December 2017. SlimBiome(R) is the first in a range of products which helps to improve human health through the science of the microbiome. Other products under development in the range include ImmunoBiome, (R) CardioBiome(R) and WellBiome(R) .

Cereal Ingredients is a privately held speciality ingredients manufacturer based in Kansas, USA, dedicated to the development, manufacture and supply of unique, high-quality food ingredients which contribute a meaningful point of difference.

Christina Wood, OptiBiotix Sales and Marketing Director, said: "Many cereals and snack bars on the market are deceptively high in sugar and calories, leading consumers with healthy intentions who use these products to gain, rather than lose, weight. By combining OptiBiotix's award winning SlimBiome(R) technology with CII's market-leading ingredients manufacturing capacity and product development, we have created a delicious functional solution which can help customers manage their weight by reducing snacking and food intake without food cravings. We are delighted to share this innovative science based approach to weight management with food and ingredient buyers from around the world at the Natural Products Expo West & Engredea show."

For more information about Optibiotix, please visit www.optibiotix.com

For further information, please contact:

 
 OptiBiotix Health plc               www.optibiotix.com 
 Stephen O'Hara, Chief Executive     Contact via 
                                      Walbrook below 
 
 Walbrook PR Ltd                   Tel: [phone] or [e-mail] 
 Anna Dunphy                         Mob: [phone] 
                                      001 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAUBSARWSAORAR

(END) Dow Jones Newswires

March 08, 2018 02:01 ET (07:01 GMT)